BioFire Diagnostics

BioFire Diagnostics. It is a clinical diagnostics company specializing in the development of syndromic testing panels for infectious diseases using multiplex PCR technology. Founded in 1990, the company is renowned for its FilmArray integrated platform, which automates the process from sample to result. A subsidiary of the French in vitro diagnostics corporation bioMérieux since 2014, it operates from its headquarters in Salt Lake City, Utah.

History

The company was originally founded in 1990 as Idaho Technology by scientists Kirk Ririe and Randy Rasmussen, focusing on rapid cycle PCR instrumentation. A pivotal shift occurred in the late 2000s with the development of the FilmArray system, leading to a corporate rebranding. In 2014, the global diagnostics firm bioMérieux acquired the company for approximately $450 million, integrating it into its portfolio of molecular diagnostics solutions. This acquisition followed significant growth driven by the commercial success of the FilmArray Respiratory Panel and expansion during public health challenges like the 2009 swine flu pandemic.

Technology

The core technology is the FilmArray system, a fully integrated, nested multiplex PCR platform housed within a single disposable pouch. This system automates nucleic acid extraction, reverse transcription, amplification, and detection, significantly simplifying complex laboratory workflows. Detection is achieved via melting curve analysis of DNA targets labeled with fluorophore-coupled primers, allowing for the simultaneous identification of numerous pathogens. The platform's design emphasizes ease of use, enabling deployment in diverse settings from large reference laboratories to hospital point-of-care testing environments.

Product portfolio

The primary product line consists of the FilmArray Torch and FilmArray 2.0 instruments, which run a comprehensive suite of syndromic testing panels. Key panels include the BioFire FilmArray Respiratory Panel, the BioFire FilmArray Blood Culture Identification Panel, and the BioFire FilmArray Gastrointestinal Panel. The portfolio also features the BioFire Defense product line, developed in collaboration with the United States Department of Defense for biothreat detection. Each panel is designed to test for a broad array of bacteria, viruses, parasites, and antimicrobial resistance genes relevant to a specific clinical syndrome.

Clinical applications

The syndromic panels are utilized across various medical disciplines to rapidly diagnose infectious diseases, directly impacting patient management and antimicrobial stewardship. In hospital-acquired infections, panels like the BioFire FilmArray Meningitis/Encephalitis Panel provide critical results for conditions such as bacterial meningitis. During the COVID-19 pandemic, the BioFire Respiratory Panel 2.1 became a vital tool for detecting SARS-CoV-2 alongside other common respiratory pathogens. This rapid, comprehensive testing aids in reducing unnecessary antibiotic use, guiding appropriate therapy, and implementing effective infection control measures in institutions like the Mayo Clinic and Cleveland Clinic.

Corporate affairs

As a wholly-owned subsidiary of bioMérieux, it operates within the Clinical Applications division of its parent company. The corporate headquarters and manufacturing facilities are located in Salt Lake City, with a significant portion of its research and development conducted there. The company maintains active collaborations with public health agencies, including the Centers for Disease Control and Prevention and the Food and Drug Administration, for panel validation and emergency use authorizations. Its products have received regulatory clearances in major markets including the European Union via the CE marking and approvals from Health Canada.

Category:Medical diagnosis companies Category:Companies based in Salt Lake City Category:bioMérieux